An examination of state and federal opioid analgesic and continuing education policies: 2016–2018

14Citations
Citations of this article
18Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Introduction: Opioid overdose deaths in the United States have climbed sharply over the past two decades. Simultaneously, increased awareness of inadequately treated chronic pain has resulted in increased opioid analgesic prescribing. The correlation between these two phenomena has led policymakers to posit that they are causally linked, and to implement policy changes supporting safe opioid prescribing. Purpose: To evaluate the impact of its Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS) program, the US Food and Drug Administration (FDA) requested the opioid manufacturers responsible for implementing that program provide information regarding opioid policy changes from 2016 to 2018. FDA also requested a survey of state requirements for pain and opioid prescribing continuing education (CE), the number of prescribers affected by those requirements, the extent to which a REMS-compliant CE program would meet each state’s requirements, and the number of relevant CE programs available. Results: Results indicate that 527 federal and state opioid-related policies (statutes, rules/ regulations, and guidelines) were approved during the 2016–2018 study period. While the largest number of these policies focused on prescription drug monitoring programs, 170 specifically imposed limits on opioid prescribing and an additional 35 specifically referred to, or incorporated, the Centers for Disease Control and Prevention opioid prescribing guideline. We also found that 46 states and the District of Columbia mandated some amount of pain or opioid prescribing CE for prescribers renewing their licenses. These mandates potentially affected as many as 1.7 million prescribers. In 69% of cases, a REMS-compliant CE program would fully meet the state mandates for various types of prescribers. Conclusion: The severity and complexity of the problems of pain management and opioid overdose have led to large-scale intervention by policymakers. Assessing the impact of these changes is difficult, at best, but will be necessary if interventions are to be refined to increase their effectiveness.

References Powered by Scopus

CDC guideline for prescribing opioids for chronic pain - United States, 2016

2543Citations
N/AReaders
Get full text

Prevalence of chronic pain and high-impact chronic pain among adults — United States, 2016

1755Citations
N/AReaders
Get full text

What we know, and don't know, about the impact of state policy and systems-level interventions on prescription drug overdose

232Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Endogenous opiates and behavior: 2020

18Citations
N/AReaders
Get full text

Exploring perspectives on changing opioid prescribing practices: A qualitative study of community stakeholders in the HEALing Communities Study

9Citations
N/AReaders
Get full text

Misinterpretation of the “Overdose Crisis” Continues to Fuel Misunderstanding of the Role of Prescription Opioids

8Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Duensing, K., Twillman, R., Ziegler, S., Cepeda, M. S., Kern, D., Salas, M., & Wedin, G. (2020). An examination of state and federal opioid analgesic and continuing education policies: 2016–2018. Journal of Pain Research, 13, 2431–2442. https://doi.org/10.2147/JPR.S267448

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 6

67%

Researcher 2

22%

Lecturer / Post doc 1

11%

Readers' Discipline

Tooltip

Medicine and Dentistry 4

40%

Pharmacology, Toxicology and Pharmaceut... 3

30%

Social Sciences 2

20%

Environmental Science 1

10%

Article Metrics

Tooltip
Social Media
Shares, Likes & Comments: 13

Save time finding and organizing research with Mendeley

Sign up for free